DS
ACAD icon

David Shaw’s Acadia Pharmaceuticals ACAD Stock Holding History

David Shaw’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-47,000
Closed -$1.42M – 3447
2017
Q4 		$1.42M Hold
47,000
– – ﹤0.01% 2376
2017
Q3 		$1.77M Hold
47,000
– – ﹤0.01% 2119
2017
Q2 		$1.31M Sell
47,000
-34,100
-42% -$1.02M ﹤0.01% 2243
2017
Q1 		$2.79M Sell
81,100
-20,000
-20% -$706K ﹤0.01% 1641
2016
Q4 		$2.92M Buy
101,100
+31,100
+44% +$823K 0.01% 1728
2016
Q3 		$2.23M Buy
70,000
+40,000
+133% +$1.36M ﹤0.01% 1846
2016
Q2 		$974K Buy
30,000
+10,000
+50% +$335K ﹤0.01% 2424
2016
Q1 		$559K Buy
+20,000
New +$436K ﹤0.01% 2722
2015
Q1 		– Sell
-134,100
Closed -$4.26M – 3586
2014
Q4 		$4.26M Hold
134,100
– – 0.01% 1689
2014
Q3 		$3.32M Hold
134,100
– – ﹤0.01% 1836
2014
Q2 		$3.03M Sell
134,100
-2,300
-2% -$48K ﹤0.01% 1983
2014
Q1 		$3.32M Sell
136,400
-42,600
-24% -$1.08M ﹤0.01% 1902
2013
Q4 		$4.47M Sell
179,000
-3,600
-2% -$84.9K 0.01% 1778
2013
Q3 		$5.02M Buy
182,600
+22,600
+14% +$472K 0.01% 1590
2013
Q2 		$2.9M Buy
+160,000
New +$2.2M 0.01% 1781

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's ACAD Position: Q2 2026 in Review

David Shaw increased its Acadia Pharmaceuticals (ACAD) stake by 133% in Q2 2026, buying an estimated $21.3M and bringing the position to 1,697,937 shares worth $43M. The position accounts for 0.02% of the portfolio, ranked #841.

David Shaw first reported a position in ACAD in Q2 2013 and has held it in 49 quarters since. The position peaked at $126M in Q2 2023. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • David Shaw held 1,697,937 shares of Acadia Pharmaceuticals worth $43M as of Q2 2026.
  • David Shaw bought 968,101 Acadia Pharmaceuticals shares in Q2 2026, an estimated $21.3M.
  • Acadia Pharmaceuticals made up 0.02% of David Shaw's portfolio in Q2 2026, its #841 holding.
  • David Shaw first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • David Shaw's Acadia Pharmaceuticals position peaked at $126M in Q2 2023.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.